- Conditions
- Healthy
- Interventions
- Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1568
of 1,568
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Placebo, JNJ-64281802 High dose, JNJ-64281802 Medium dose, JNJ-64281802 Low dose, JNJ-64281802 Dosing Regimen X, JNJ-64281802 Dosing Regimen Y, JNJ-64281802 Dosing Regimen Z
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Interventions
- Intra-lymphatic allergenic extract, Intra-lymphatic placebo
- Biological
- Lead sponsor
- Christopher Thompson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Austin, Texas • Grapevine, Texas • San Antonio, Texas
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more
- Conditions
- Turner Syndrome
- Interventions
- somatotropin
- Drug
- Lead sponsor
- Rebecca Knickmeyer Santelli, PhD
- Other
- Eligibility
- 11 Months to 13 Months · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
- Interventions
- Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
- Device · Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Interventions
- CMP-001, Nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more
- Conditions
- Analgesia
- Interventions
- Bupivacaine Hydrochloride, HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Sarasota, Florida • Tulsa, Oklahoma + 4 more